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Received June 2, 2016; accepted August 18, 2016AbstractBackground: The aim of this study was to review the experience of surgical treatment of low-grade chondrosarcoma and to assess the long-term
oncological and functional outcomes between intralesional curettage and wide excision.
Methods: We included 11 patients with central low-grade chondrosarcoma lesions treated with intralesional curettage or wide excision from
1998 to 2013. Seven patients were treated with intralesional curettage and local adjuvant treatment (Group A), and four patients were treated
with wide excision and reconstructive surgery (Group B). The mean age of patients was 43.8± 17.6 years (range, 20e71 years), and the mean
duration of follow-up was 84.4 ± 47.6 months (range, 48e194 months).
Results: Group A had a significantly lower complication rate than Group B; three complications were documented in Group B (0% vs. 75%,
p¼ 0.024). The operative time (177.1 hours vs. 366.3 hours, p¼ 0.010) and the hospital stay (6.6 days vs. 12.5 days, p¼ 0.010) were
significantly shorter in Group A. There was one local recurrence in Group A without statistical significance. Also, there were no differences
between intralesional curettage and wide excision with respect to the blood loss. No metastasis disease occurred in either group during the
follow-up period. The Musculoskeletal Tumor Society (MSTS) scores in Groups A and B were 99.0± 2.5 and 94.2 ± 4.2, respectively, with
statistically significant difference ( p¼ 0.048).
Conclusion: Extended intralesional curettage has the benefits of good MSTS score, shorter operative time, shorter hospital stay, and lower
complication rate without increasing local recurrence in central low-grade chondrosarcoma. For central low-grade chondrosarcoma, we suggest
extended curettage to decrease soft tissue damage and surgical risk.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mation. The pelvis, femur, and shoulder girdle are the most
common sites of chondrosarcoma; the incidence at spine was
reported at about 12%.2,3 Central chondrosarcoma may grow
primarily in the medullary cavity of bone. The prognosis of
central chondrosarcoma is related to its pathophysiology
grading. The histologic classification of Evans et al4 depends
on cellularity, cellular atypia, and mitosis. Grade 1 chon-
drosarcoma is classified as low-grade lesions, and grade 2 and
grade 3 are classified as high-grade neoplasms. The principle
modality of treatment for chondrosarcoma is en bloc surgicalntral low-grade chondrosarcoma: A midterm follow-up study, Journal of the
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Table 2
Summary of the outcome data.
Group Aa
(n¼ 7)
Group Bb
(n¼ 4)
Total p
Sex (M/F) 3/4 1/3
Age (y) 34.0± 13.3 61.0± 7.7 43.8± 17.6 0.001
Lesion size (cm) 6.9± 5.1 12.5± 3.1 8.9± 2.7 0.216
Operative time (mins) 177.1± 83.5 366.3± 98.4 245.9± 127.3 0.010
Blood loss (mL) 428.6± 485.5 1162.5± 1164.3 695.5± 827.8 0.151
Follow-up (months) 72.9± 63.1 61.3± 23.2 68.7± 50.9 0.336
Local recurrence 1 0 1 0.636
Complication 0 3 3 0.024
Metastasis or death 0 0 0
Hospital stay (d) 6.6± 2.8 12.5± 3.1 8.7± 4.1 0.010
MSTS scores (%) 99.0± 2.5 94.2± 4.2 97.3± 3.9 0.048
F¼ female; M¼male; MSTS¼Musculoskeletal Tumor Society.
a Group A¼ patients treated with intralesional curettage.
b Group B¼ patients treated with wide excision.
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and radiation treatment.5,6 Recently, low-grade chon-
drosarcoma of long bones has increasingly been treated with
intralesional curettage and local adjuvant therapy due to its
slow growth and low metastatic tendency.5,7 However, some
authors argued that inadequate local treatment with an intra-
lesional management results in higher local recurrence.8e10
We hypothesized that advanced intralesional treatment, using
chemical agents and cryoablation, for central grade I chon-
drosarcomas would have similar rates of local recurrence and
metastasis as wide excision treatment. The aims of this
retrospective study were to review the experience of surgical
treatment of central low-grade chondrosarcoma, to assess the
long-term clinical and oncological outcomes between intra-
lesional curettage and wide excision, and to compare the re-
sults of the two surgical managements.
2. Methods
A retrospective search of our departmental database iden-
tified 48 patients with low-grade chondrosarcoma from 1998
to 2013. We excluded 3 patients with locally recurrent or
metastatic disease at present and 22 patients diagnosed with
so-called borderline, Grade 1e2 chondrosarcoma from pre-
operative biopsy. In addition, we excluded three patients with
secondary chondrosarcoma, two with extraosseous lesions,
and seven with stage IB chondrosarcoma.11 The final cohort
included 11 patients whose medical records, histological
sections, and radiography were reviewed.
The patients were divided into two groups; patients in
Group A (n¼ 7) were treated with extended intralesional
curettage, whereas patients in Group B (n¼ 4) were treated
with wide excision and reconstructive surgery (Table 1). The
tumors affected appendicular bone in eight patients (75%) and
axial bone in three patients (25%). There were three distal
femurs (two in Group A and one in Group B), one proximal
femur (Group A), three proximal humerus (two in Group A
and one in Group B), one humeral shaft (Group B), and three
acetabulums (two in Group A and one in Group B).
In our database, low-grade chondrosarcoma represented
48.5% (48/99) of all chondrosarcoma patients, and stage IATable 1
Demographic data of the patients in the study.
Patient Sex Age (y) Location Follow-up time
(months)
Size
(cm)
1 F 36 Acetabulum 140.0 5
2 M 36 Distal femur 48.0 8
6 M 20 Distal femur 58.0 18
4 F 21 Acetabulum 49.0 6
10 F 24 Proximal humerus 119.1 4.6
11 F 55 Proximal humerus 194.1 4
7 M 46 Proximal femur 60.4 3
8 F 54 Distal femur 71.3 7.5
9 M 71 Proximal humerus 88.2 10
5 M 63 Humeral shaft 50.4 6
3 F 56 Acetabulum 50.0 12
DCP¼ dynamic compression plate; F¼ female; M¼male; MSTS¼Musculoskele
Please cite this article in press as: Chen Y-C, et al., Intralesional curettage of ce
Chinese Medical Association (2016), http://dx.doi.org/10.1016/j.jcma.2016.10.00chondrosarcoma accounted for 22.9% of low-grade patients.
There were six male and five female patients with a mean age at
surgery of 43.8 ± 17.6 years (range, 20e71 years), with a sig-
nificant difference ( p¼ 0.006) in age between treatment cohorts
(Table 2). The average duration of follow-up for the patients was
68.7± 50.9 months (range, 19e194 months). The average
lesion size was 8.9± 2.7 cm (range, 3e18cm, p¼ 0.216).
The surgical indication in our institution was painful lesion
with aggressive radiologic patterns. All the patients had pre-
operative pathology, either needle biopsy or excisional biopsy,
with the specimen reviewed by two experienced pathologists.
Imaging study, computed tomography (CT) scan, or magnetic
resonance imaging (MRI) was also obtained to evaluate bone
expansion, tumor length, and active periostitis. Depending on
the site and size of the tumor, we explained the surgical
management options, extended curettage and wide excision,
and their respective disadvantages and advantages to the pa-
tient and/or their family. The surgeon and patient together
made the final surgical management decision. For the ace-
tabulum lesion, two of the three patients chose intralesional
curettage to minimize the surgical risk. For the periarticular
chondrosarcoma, we performed reconstructive surgery after
wide excision to restore the function of the patient. In someTreatment Additional treatment MSTS
score
Curettage Allograft 93%
Curettage Liquid nitrogen, allograft 100%
Curettage Liquid nitrogen, tibia allograft 100%
Curettage Autograft, total hip arthroplasty 100%
Curettage Allograft 100%
Curettage Allograft 100%
Curettage Allograft, DCP 100%
Wide excision Nitrogen, total knee arthroplasty 90%
Wide excision Extracoporeal irradiation, broad DCP, cement 93%
Wide excision Liquid nitrogen, philus locking plate 100%
Wide excision Total hip arthroplasty, extracoporeal irradiation 93%
tal Tumor Society.
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Fig. 1. Adjuvant treatment with cryotherapy. Liquid nitrogen was sprayed out
from the can toward the remaining cavity. The soft tissue was protected with
warm gauzes.
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cled bone prepared by extracorporeal irradiation with 20,000
rad or liquid nitrogen soaking. For the patients of curettage,
we removed the lesions macroscopically using curets and
high-speed burr when the margin was well protected with
warm gauze to prevent contamination by spray (Fig. 1). The
margin of the lesion was determined by both the cortical
border and intramedullary canal, which were mapped by MRI
or CT scan preoperatively. A solution of phenol was applied to
the remaining bone cavity for 3 minutes with a surgical swab,
and then the cavity was rinsed with 95% ethanol solution.
Subsequently, massive normal saline (> 2000 mL) irrigation
was performed. Cryotherapy with liquid nitrogen was used in
selected patients who could be safely applied without injury ofFig. 2. (A) Patient 4 had the tumor lesion at left acetabulum (arrow); (B) T2-weighte
done after intralesional treatment with adjuvant therapy. MRI¼magnetic resonanc
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Chinese Medical Association (2016), http://dx.doi.org/10.1016/j.jcma.2016.10.00surrounding soft tissues. Finally, the defect that was made by
curettage was filled with allograft bone chips, and if necessary,
internal fixation was applied to reinforce the affected bone.
For Patients 3, 4, and 8, arthroplasty was also performed to
address destruction of articular surface (Fig. 2).
The primary outcome was local recurrence or metastasis.
The secondary outcome included functional outcome based on
Musculoskeletal Tumor Society (MSTS) score. Data for the
study were retrieved from hospital records, maintained onco-
logical files, surgical files, and clinical examination at the most
recent outpatient clinic. These data included surgical time,
blood loss, complications, incidence of local recurrence, and
distant metastases. Approval for the study was obtained from
the Institutional Review Broad. We analyzed the resulting data
using Student t test, Fisher's exact test, and analysis of vari-
ance, with a significance threshold of p < 0.05 using STATA
software version 12.1 (STATA, College Station, Texas, USA).
3. Results
The average amount of intraoperative blood loss was
428.6± 485.5 mL in Group A and 1162.5 ± 1164.3 mL in
Group B ( p¼ 0.151). There was a significant difference in the
operative time ( p¼ 0.010) between Group A (177.1 ± 83.5,
range 60e320 minutes) and Group B (366.3 ± 98.4, range
300e510 minutes). Additionally, the hospital stay was
significantly shorter ( p¼ 0.048) in Group A (6.6 ± 2.8, range
4e12 days) than in Group B (12.5± 3.1, range 9e16 days).3.1. ComplicationsThere were three complications in Group B, including one
nonunion at distal femur (Patient 8), one hip dislocation atd MRI showed periarticular involvement (arrow); (C) total hip arthroplasty was
e imaging.
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Fig. 3. The local recurrence-free survival was 85.7% in Group A, patients
treated with intralesional curettage, versus 100% in Group B, patients treated
with wide excision ( p¼ 0.638).
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proximal humerus (Patient 9). No complication was docu-
mented in Group A. The complication rate was significantly
higher in Group B than in Group A (0% vs. 75%, p¼ 0.024).3.2. OutcomesThe MSTS score was significantly better ( p¼ 0.048) in
Group A (99.0 ± 2.5%) than in Group B (94.2 ± 4.2%).3.3. Local recurrenceThere was one local recurrence at distal femur in Group A
(Patient 6), and the duration of local recurrence was 19
months. There was no difference ( p¼ 0.636) in local recur-
rence rate between the study cohorts (Fig. 3). The local
recurrence-free survival estimate was 90.0 ± 9.5% (95% con-
fidence interval¼ 0.4730e0.9853). The overall recurrence
rate in our study was 9.1%.3.4. Metastasis and survivalThere was no metastasis in either group. Patient 9 died of
another disease (pneumonia) during the follow-up, at 88
months. No patient died due to chondrosarcoma during the
follow-up in both the groups.
4. Discussion
The principle of surgery for high-grade sarcoma is to obtain a
wide margin including amputation and wide excision with
reconstruction. However, the surgical management of low-
grade chondrosarcoma has remained under debate in recent
years due to its low potential metastasis and local recurrence.
These characteristics of low-grade chondrosarcoma provide the
possibility of a more conservative approach with less soft tissue
damage. Therefore, some studies are advocated using extended
intralesional curettage, which was an option for benignPlease cite this article in press as: Chen Y-C, et al., Intralesional curettage of ce
Chinese Medical Association (2016), http://dx.doi.org/10.1016/j.jcma.2016.10.00aggressive tumors of bone, for patients with low-grade
chondrosarcoma.12e15 There are several adjuvant methods for
extended intralesional curettage, such as phenol application,13
cauterization,12,15 or cryotherapy16 followed by either cemen-
tation17 or bone grafting. Previous studies have demonstrated
that these adjuvant treatments are necessary for control of local
recurrence.14,18 In our patients, cauterization with phenol and
alcohol was routinely launched in the curettage technique.
However, liquid nitrogen was used in selected patients due to
comorbid condition or location of the tumor lesion. Also, the
surrounding soft tissue with warm gauze was well covered for
protection when applying liquid nitrogen. Under this condition,
we performed cryotherapy in two patients (28.6%), and we
suggest that long bone was good indication for adjuvant cryo-
therapy due to its anatomy and the ease of application.
We believe either wide excision or extended intralesional
curettage could be used for low-grade chondrosarcoma only if
the tumor lesion would be totally removed. There was one
patient of recurrence treated with curettage in our study. That
case had cortical breakthrough which was noted intra-
operatively. Meftah et al reported that soft tissue extension was
strongly associated with local recurrence after curettage and
cryotherapy.19 In our patients, we regarded cortical break-
through and soft tissue extension of low-grade chon-
drosarcoma as adverse factors for local control.
Some authors reported that local treatment led to higher local
recurrence rates due to an inadequate surgical margin.8e10
Some others reported that intralesional curettage wound not
increase the recurrence rates.12,17,19,20 The discrepancy of the
results may be related to the extent of the curettage. The overall
recurrence rate of low-grade chondrosarcoma after treatment in
our study was 9.1%, and the respective recurrence rate was
14.3% in the Group A. Therewas no recurrence in Group B, and
there was no statistically significant difference ( p¼ 0.636) in
the study cohort. However, some studies suggested that axial
lesion of central low-grade chondrosarcoma was an adverse
factor for local recurrence after curettage.19,20 In our experi-
ence, axial lesions are difficult to approach on anatomy, and the
local adjuvant treatment may be difficult to achieve. We agreed
that long bone was good indication for extended intralesional
curettage with adjuvant local treatment.
In our study, the patient and the surgeon decided on the
index surgery after evaluating surgical risk and possibility of
local recurrence. The patient age was significant lesser in the
Group A ( p¼ 0.001). The young patients might prefer host
bone restored and less soft tissue damage in order to reserve
function even though they had to take the risk of local
recurrence. Tumor size showed no statistically significant
difference ( p¼ 0.177) between the groups. We expected that
patients treated with extended curettage would have less blood
loss; however, our study showed no significant difference
( p¼ 0.151). It might be easy bleeding of bone marrow which
resulted in increasing blood loss during curettage. The surgical
time was shorter in Group A ( p¼ 0.01). Also, Group A had a
significantly short hospital stay ( p¼ 0.010). This result was
encouraging and implied less soft tissue damage and more
rapid recovery.ntral low-grade chondrosarcoma: A midterm follow-up study, Journal of the
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score after curettage treatment was 99%, better than that in
previous studies, which ranged from 90% to 93%.7,16,21 Two
cohort studies showed higher MSTS scores for patients who
underwent intralesional curettage than those who underwent
wide resection (98% vs. 84% and 89% vs.72%);12,22 in our
study, we had similar results with 99% vs. 94%. Additionally,
the MSTS score was significantly different ( p¼ 0.048) be-
tween the two groups.
Previous studies have reported lower complication rates after
intralesional treatment than those after wide resection.12,13,23 In
our study, there was no complication in the Group A; on the
contrary, in Group B, three complications were documented,
including nonunion of recycled bone, dislocation of hip pros-
thesis, and periprosthetic fracture, after minor trauma. Several
studies also reported high complication rates after major
endoprosthetic or allograft reconstructions.24,25 Due to the
small sample size of our study, the difference between
complication rates had no statistical significance. We believe
that management with wide excision and reconstruction led to a
higher complication rate. On the contrary, extended curettage
might have lower complication rate and reduce subsequent
surgical procedure in central low-grade chondrosarcoma.
Our study had several limitations. First, this was a retro-
spective analysis. Second, the study group sample sizewas small.
The rarity of this pathology makes it difficult to enroll a large
number of patients in a short period; therefore, multi-institution
study should be considered in the future. Third, comparison of
different treatments (curettage vs. wide excision) was not ran-
domized and had no firm protocol. Finally, the length of follow-
up of our patients was considerable, but still not long enough to
make definitive conclusions about oncological outcomes.
In conclusion, we found that extended curettage treatment
provided safe procedure for central low-grade chondrosarcoma
and had the benefits of shorter hospital stay, shorter operative time,
lower complication rate, and good functional score without
increasing local recurrence. For central low-grade chon-
drosarcoma, extended curettage may be the first choice in long
bone andmaybe a goodelectivemanagement in theaxial skeleton.References
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